PMC:7536913 / 8762-9629 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T6","span":{"begin":382,"end":387},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma7088"}],"text":"In order to rapidly accelerate the development and manufacturing scale‐up of COVID‐19 therapeutics, industry and regulators continue to partner in quick fashion to adopt fit‐for‐purpose regulatory strategies. Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses. Such life‐threatening diseases will continue long after COVID‐19 is managed, and it will be important not to revert to previous practices and to emerge from the current situation with enduring solutions for the benefit of patients, globally. This objective will challenge each stakeholder to implement processes that enable regulators to prioritize and focus on the most important, unmet needs with the most substantial public health impacts."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T5","span":{"begin":65,"end":70},"obj":"Body_part"},{"id":"T6","span":{"begin":382,"end":387},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"In order to rapidly accelerate the development and manufacturing scale‐up of COVID‐19 therapeutics, industry and regulators continue to partner in quick fashion to adopt fit‐for‐purpose regulatory strategies. Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses. Such life‐threatening diseases will continue long after COVID‐19 is managed, and it will be important not to revert to previous practices and to emerge from the current situation with enduring solutions for the benefit of patients, globally. This objective will challenge each stakeholder to implement processes that enable regulators to prioritize and focus on the most important, unmet needs with the most substantial public health impacts."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T25","span":{"begin":77,"end":85},"obj":"Disease"},{"id":"T26","span":{"begin":260,"end":268},"obj":"Disease"},{"id":"T27","span":{"begin":382,"end":395},"obj":"Disease"},{"id":"T28","span":{"begin":481,"end":489},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005252"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In order to rapidly accelerate the development and manufacturing scale‐up of COVID‐19 therapeutics, industry and regulators continue to partner in quick fashion to adopt fit‐for‐purpose regulatory strategies. Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses. Such life‐threatening diseases will continue long after COVID‐19 is managed, and it will be important not to revert to previous practices and to emerge from the current situation with enduring solutions for the benefit of patients, globally. This objective will challenge each stakeholder to implement processes that enable regulators to prioritize and focus on the most important, unmet needs with the most substantial public health impacts."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T45","span":{"begin":382,"end":387},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T46","span":{"begin":382,"end":387},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T47","span":{"begin":382,"end":387},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T48","span":{"begin":382,"end":387},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T49","span":{"begin":672,"end":681},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"},{"id":"T50","span":{"begin":778,"end":783},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"In order to rapidly accelerate the development and manufacturing scale‐up of COVID‐19 therapeutics, industry and regulators continue to partner in quick fashion to adopt fit‐for‐purpose regulatory strategies. Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses. Such life‐threatening diseases will continue long after COVID‐19 is managed, and it will be important not to revert to previous practices and to emerge from the current situation with enduring solutions for the benefit of patients, globally. This objective will challenge each stakeholder to implement processes that enable regulators to prioritize and focus on the most important, unmet needs with the most substantial public health impacts."}

{"project":"LitCovid-PubTator","denotations":[{"id":"79","span":{"begin":269,"end":277},"obj":"Species"},{"id":"80","span":{"begin":320,"end":328},"obj":"Species"},{"id":"81","span":{"begin":647,"end":655},"obj":"Species"},{"id":"82","span":{"begin":77,"end":85},"obj":"Disease"},{"id":"83","span":{"begin":260,"end":268},"obj":"Disease"},{"id":"84","span":{"begin":382,"end":395},"obj":"Disease"},{"id":"85","span":{"begin":481,"end":489},"obj":"Disease"}],"attributes":[{"id":"A79","pred":"tao:has_database_id","subj":"79","obj":"Tax:9606"},{"id":"A80","pred":"tao:has_database_id","subj":"80","obj":"Tax:9606"},{"id":"A81","pred":"tao:has_database_id","subj":"81","obj":"Tax:9606"},{"id":"A82","pred":"tao:has_database_id","subj":"82","obj":"MESH:C000657245"},{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"MESH:C000657245"},{"id":"A84","pred":"tao:has_database_id","subj":"84","obj":"MESH:D006333"},{"id":"A85","pred":"tao:has_database_id","subj":"85","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In order to rapidly accelerate the development and manufacturing scale‐up of COVID‐19 therapeutics, industry and regulators continue to partner in quick fashion to adopt fit‐for‐purpose regulatory strategies. Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses. Such life‐threatening diseases will continue long after COVID‐19 is managed, and it will be important not to revert to previous practices and to emerge from the current situation with enduring solutions for the benefit of patients, globally. This objective will challenge each stakeholder to implement processes that enable regulators to prioritize and focus on the most important, unmet needs with the most substantial public health impacts."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T3","span":{"begin":348,"end":369},"obj":"Phenotype"},{"id":"T4","span":{"begin":382,"end":395},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001635"}],"text":"In order to rapidly accelerate the development and manufacturing scale‐up of COVID‐19 therapeutics, industry and regulators continue to partner in quick fashion to adopt fit‐for‐purpose regulatory strategies. Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses. Such life‐threatening diseases will continue long after COVID‐19 is managed, and it will be important not to revert to previous practices and to emerge from the current situation with enduring solutions for the benefit of patients, globally. This objective will challenge each stakeholder to implement processes that enable regulators to prioritize and focus on the most important, unmet needs with the most substantial public health impacts."}

{"project":"LitCovid-sentences","denotations":[{"id":"T60","span":{"begin":0,"end":208},"obj":"Sentence"},{"id":"T61","span":{"begin":209,"end":424},"obj":"Sentence"},{"id":"T62","span":{"begin":425,"end":666},"obj":"Sentence"},{"id":"T63","span":{"begin":667,"end":867},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In order to rapidly accelerate the development and manufacturing scale‐up of COVID‐19 therapeutics, industry and regulators continue to partner in quick fashion to adopt fit‐for‐purpose regulatory strategies. Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses. Such life‐threatening diseases will continue long after COVID‐19 is managed, and it will be important not to revert to previous practices and to emerge from the current situation with enduring solutions for the benefit of patients, globally. This objective will challenge each stakeholder to implement processes that enable regulators to prioritize and focus on the most important, unmet needs with the most substantial public health impacts."}